RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Real-world treatment patterns in patients with EGFR mutation-positive NSCLC receiving a first-line, first- or second-generation EGFR tyrosine kinase inhibitor in South Korea and Taiwan
Lee, J. C., Hung, J., Kim, Y., Chang, G., Yoo, S. S., Yang, S., Davis, K. L., Nagar, S. P., Taylor, A., Lee, S. Y., & Shih, J. (2021). Real-world treatment patterns in patients with EGFR mutation-positive NSCLC receiving a first-line, first- or second-generation EGFR tyrosine kinase inhibitor in South Korea and Taiwan. Asian Pacific Journal of Cancer Biology, 6(2), 123-132. https://doi.org/10.31557/apjcb.2021.6.2.123-132